FDA grants Fast Track designation to nomacopan for treatment of patients with moderate and severe bullous pemphigoid (BP)

Nomacopan, a second-generation complement inhibitor which acts on complement component-C5, and also inhibits leukotriene B4 activity, is claimed to have the potential to replace long term steroid treatment (standard of care) in BP. A phase III study has been initiated.

Source:

Biospace Inc.